#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Clinical Biochemistry and Metabolism / 2025 - 1

Výzvy a perspektivy diagnostiky demencí

Download PDF English version

Authors: I. Lochman 1,2;  R. Novobilský 3,4,5;  P. Kušnierová 2,3
Authors‘ workplace: Spadia Lab, Ostrava 1;  Ústav laboratorní medicíny Lékařské fakulty Ostravské university 2;  Ústav laboratorní medicíny Fakultní nemocnice, Ostrava 3;  Katedra klinických neurověd Lékařské fakulty Ostravské university 4;  Neurologická klinika Fakultní nemocnice Ostrava 5
Published in: Klin. Biochem. Metab., 33, 2025, No. 1, p. 16-22
Category: Review articles
doi: https://doi.org/10.61568/kbm.2025.007

Overview

Záměrem tohoto sdělení je ukázat současné možnosti racionálního příspěvku laboratorních metod v diagnostice, vyhledávání a péči o pacienty s demencemi, především Alzheimerovou chorobou (AD). Předpokládá se, že počty jedinců postižených těmito chorobami porostou a v r. 2050 budou dosahovat zhruba dvojnásobných hodnot oproti současnému stavu. Proto je nezbytné zabývat se hledáním optimálního řešení zajištění komplexní péče o takto postižené osoby, která by byla dostupná a ekonomicky akceptovatelná. Laboratorní diagnostika bude hrát v této oblasti bezpochyby významnou úlohu.

Klíčová slova:

diagnostika demence – současné možnosti a potřeby

Sources
  1. Reuben, D. B., Kremen, S., Maust, D. T. Dementia prevention and treatment. A narrative review. JAMA Intern. Med., 2024, 184(5), 563-572. 
  2. Clifford, R. J., Andrews, J. S., Beach, T. G. et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia.
  3. No authors listed. 2024 Alzheimer's disease facts and figures. Alzheimers Dement., 2024, 20(5), 3708-3821. 
  4. Dubois, B., Villain, N., Schneider, L et al. Alzheimer Disease as a Clinical-Biological Construct -⁠ An International Working Group Recommendation. JAMA Neurol., 2024, 81(12), 1304-1311. 
  5. Resner, P., Hort, J., Rektorová, I., et al. Doporučené postupy pro diagnostiku Alzheimerovy nemoci a dalších onemocnění spojených s demencí. Cesk. Slov. Neurol. N, 2008, 71/104(4), 494-501.
  6. Arevalo-Rodriguez, I., Smailagic, N., Roqué-Figuls, M., Ciapponi, A., Sanchez-Perez, E., Giannakou, A., Pedraza, O. L., Bonfill Cosp, X., Cullum, S. Mini -⁠ Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev., 2021, 7(7), CD010783. 
  7. Štěpánková, H., Nikolai, T., Lukavský, J., et al. Mini -⁠ Mental State Examination -⁠ česká normativní studie. Cesk. Slov. Neurol. N, 2015, 78/111(1), 57-63.
  8. Nasreddine, Z. S., Phillips, N. A., Bédirian, V., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment, J Am. Geriatr. Soc., 2005, 53(4), 695-699. 
  9. Krupa, P., Pažourková, M. Zobrazovací metody v neurologii. Neurol. pro Praxi, 2005, 3, 128-132.
  10. Chouliaras, L., O'Brien, J. T. The use of neuroimaging techniques in the early and differential diagnosis of dementia. Mol. Psychiatr., 2023, 28, 4084-4097. 
  11. Vogel, A. C., Black, K. J. Brain imaging in routine psychiatric practice. Mo. Med., 2024, 21(1), 37-43
  12. Young, P. N. E., Estarellas, M., Coomans, E. et al. Imaging biomarkers in neurodegeneration: current and future practices, Alz. Res. Therapy, 2020, 12, 49. 
  13. Pereira, A. F., Simões do Couto, F., de Mendonça, A. The use of laboratory tests in patients with mild cognitive impairment. J Alzheimer. Dis., 2006, 10(1), 53 -⁠ 58. 
  14. Palmqvist, S., Tideman, P., Mattsson-Carlgren, N. et al. Blood biomarkers to detect Alzheimer Disease in primary care and secondary care. JAMA, 2024, 332(15), 1245-1257. 
  15. Salloway, S., Rowe, C., Burns, J. M. Are blood tests for Alzheimer Disease ready for prime time? JAMA, 2024, 332(15), 1240-1241. 
  16. Jack, C. R., Andrews, J. S., Beach, T. G. et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer Dement., 2024, 20, 5143-5169. 
  17. Kivisäkk, P., Fatima, H. A., Cahoon, D. S. et al. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer's disease. Scientific Reports, 2024, 14, 629. 
  18. Hanes, J., Kovac, A., Kvardsberg, H. et al. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035. 
  19. Horie, K., Salvadó, G., Barthélemy, N. R. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nat. Med., 2023, 29, 1954-1963 
  20. Harris, E. Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease. JAMA, 2024, 331(24), 2070-2071 
  21. Fortea, J., Pegueroles, J., Alcolea, D. et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease. Nat. Med., 2024, 30, 1284-1291. 
  22. Hoilund-Carlsen, P. F., Alavi, A., Barrio, J. R. et al. Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village. Ageing Res. Rev., 2024, 93, 102173. 
  23. Chen, Y., Holtzman, D. M. New insights into innate immunity in Alzheimer's disease: from APOE protective variants to therapies. Trends Immunol., 2024, 45(10), 768-782. 
  24. Čechová, K., Chmátalová, Z., Matušková, V. et al. APOE a BDNF jako rizikové genetické markery pro predikci nástupu a rozvoje kognitivního deficitu při Alzheimerově nemoci. Cesk. Slov. Neurol. N, 2020, 83/116(3), 257-262. 
  25. Brooks, M. Finger-Prick Test for Alzheimer's Disease? Medscape Medical News, 2024, November 01, CTAD 2024a.
  26. Tao, Q.-Q., Cai, X., Xue, Y.-Y. et al. Alzheimer's disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling. The Innovation, 2024, 5(1), 100544. 
  27. Zhang, D., Zhang, W., Ming, C. et al. P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy. Neuron, 2024, 112(10), 1676-1693. 
  28. Ashton, N. J., Brum, W. S., Di Molfetta, G. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol., 2024, 81(3), 255-263. 
  29. Barthélemy, N. R., Salvadó, G., Schindler, S. E. et al. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med., 2024, 30, 1085-1095. 
  30. Garcia-Escobar, G., Manero, R. M., Fernandez -⁠ Lebrero, A. et al. Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review. Biomolecules, 2024, 14(1), 93. 
  31. Janelidze, S., Barthélemy, N. R., Salvadó, G., et al. Plasma phosphorylated Tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment. JAMA Neurol., 2024, 81(9), 947-957. 
  32. Chen, G.-F., Xu, T.-H., Yan. Y. et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica, 2017, 38, 1205-1235. 
  33. Frost, G. R., Li, Y.-M. The role of astrocytes in amyloid production and Alzheimer's disease. Open Biol., 2017, 7 170228. 
  34. Avila, J., Lucas, J.J., Perez, M., Hernandez, F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev., 2004, 84(2), 361-84. 
  35. Khalil, M., Teunissen, C.E., Lehmann, S. et al. Neurofilaments as biomarkers in neurological disorders -⁠ towards clinical application. Nat. Rev. Neurol., 2024, 20, 269-287. 
  36. Kim, K. Y., Shin, K. Y., Chang, K. A. GFAP as a potential biomarker for Alzheimer's Disease: A systematic review and meta-analysis. Cells, 2023, 12(9), 1309. 
  37. Mohelská, H., Náklady léčby Alzheimerovy choroby v ČR -⁠ Případová studie za období 2010-2014. Ekonomie ve zdravotnictví, 2017/1, Czech Edition.
  38. Boa Sorte Silva Nárlon, C., Barha, C.K., Erickson, K. I. et al. Physical exercise, cognition, and brain health in aging. Trends Neurosci., 2024, 47(6), 402-417. 
  39. Satija, B., Steenhuvsen, J. Lilly Alzheimer's drug gets unanimous backing from FDA advisory panel Reuters, 2024
  40. Novak, P., Kontsekova, E., Zilka, N., Novak, M. Ten years of Tau-Targered Immunotherapy: The Path Walked and the Roads Ahead. Front. Neurosci., 2018, 12, 798. 
  41. Jovasevic, V., Wood, EM., Cicvaric, A. et al. Formation of memory assemblies through the DNA-sensing TLR9 pathway. Nature, 2024, 628, 145-153. 
  42. Brooks, M. Novel Cell-Based Therapy Promising for Alzheimer's Disease.
  43. Brody, M., Agronin, M., Herskowitz, B. J., Bookheimer, S. Y. et al. Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease. Alzheimers Dement., 2023, 19(1), 261-273. 
  44. Sacristán, C. Partners and guardians of the nervous and immune systems. Trends Immunol., 2024, 45 (5), 315-17. 
  45. Boskovic, P., Gao, W., Kipnis, J. Will cellular immunotherapies end neurodegenerative diseases? Trends Immunol., 2024, 45(5), 329-337. 
  46. Maci, T., Le Pira, F., Quattrocchi, G. et al. Physical and Cognitive Stimulation in Alzheimer Disease. The GAIA Project. A Pilot Study. Am. J Alzheimers Dis. Other Demen., 2012, 27(2), 107-113. 
  47. De la Rosa, A., Olaso-Gonzalez, G., Arc-Chagnaud, C. et al. Physical exercise in the prevention and treatment of Alzheimer's disease. J Sport Health. Sci., 2020, 9, 394-404. 
  48. Pagotto, G. L. O., Santos, L. M. O. D., Osman, N., Lamas, C. B., et al. Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer's Dementia: Clinical Trial Systematic Review. Antioxidants (Basel), 2024, 13(6), 651. 
  49. Machado, M. M. F., Banin, R. M., Thomaz, F. M., de Andrade, I. S. et al. Ginkgo biloba Extract (GbE) Restores Serotonin and Leptin Receptor Levels and Plays an Antioxidative Role in the Hippocampus of Ovariectomized Rats. Mol. Neurobiol., 2021, 58(6), 2692-2703. 
  50. Huang, I. C., Chang, T. S., Chen, C., Sung, J. Y. Effect of Vortioxetine on Cognitive Impairment in Patients with Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Int. J Neuropsychopharmacol., 2022, 25(12), 969-978. 
  51. Ribeiro, F. C., Cozachenco, D., Argyrousi, E. K. et al. The ketamine metabolite (2R,6R)-hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer's disease. Alzheimers Dement., 2024, 20(8), 5398-5410 
Labels
Clinical biochemistry Nuclear medicine Nutritive therapist
Examination of less common body fluids: part 1 - pleural fluid.
Diagnostika akutního kardiálního poškození a infarktu. Cesta k strojovému učení a personalizaci otevřena?
Inovace laboratorních vyšetření u chronické ledvinové choroby
Article was published in

Clinical Biochemistry and Metabolism

Issue 1
2025 Issue 1
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#